Difficulty: Medium
Average Score: 62%
Practice
Which of the following new drug is indicated in managing SIADH, non ├â┬ó├óÔÇÜ┬¼├óÔé¼┼ô peptide and competitive antagonist of ADH├â┬ó├óÔÇÜ┬¼├óÔÇ×┬ós water sparing effects in the collecting ducts of nephron?
Correct answer
D
Rationale
The correct answer is D: Conivaptan. Conivaptan is a non-peptide competitive antagonist of ADH, indicated for managing SIADH by blocking ADH's water-sparing effects in the collecting ducts. Mannitol (A) is an osmotic diuretic used for reducing intracranial pressure, not specifically for SIADH. Bumetanide (B) is a loop diuretic used for conditions like heart failure and edema. Spironolactone (C) is a potassium-sparing diuretic used for conditions like hypertension and heart failure, not specifically for SIADH.